TUSTIN, CA--(Marketwire - May 25, 2010) - Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based pharmaceutical company specializing in the research, development and sales of In Vitro Diagnostic (IVD) cancer tests, is sad to announce the death of RPC board member Edward R. Arquilla M.D. Ph.D. Dr. Arquilla joined RPC’s Board of Directors in 1997 and supported the Company with corporate and scientific planning. He also served as a liaison to the clinical and academic communities.
Dr. Arquilla innovatively obtained the very first patent for a pregnancy test in 1964 and published over 80 different scientific articles spanning a diverse range of medical topics. He was a full time faculty member of the Departments of Pathology at the University of Southern California (USC), the University of California at Los Angeles (UCLA) and the University of California at Irvine (UCI). He was also a Professor and Chair of Pathology at UCI Chief of Pathology services at UCI Medical Center from 1968 until 1986 where he established the UCI Pathology referral services. He had an active interest in applying immunology to diagnostic testing throughout the past fifty years and was among the first to develop immunological tests to measure levels of proteins and hormones.
“Dr. Arquilla joined RPC’s Board in 1997 and has been a pillar of scientific, medical and business expertise and insight for RPC for more than a dozen years,” said Douglas MacLellan, Executive Chairman and CEO of RPC. “It has been a privilege to know and work with Ed, and we’re going to miss him dearly.”
Dr. Arquilla was a very active member of the American Diabetes Association and the Juvenile Diabetes Foundation International. He received a B.S. degree from Northern Illinois University in 1947, an M.S. in Physiology from the University of Illinois in 1949, and M.D. from Western Reserve University in 1955 and a Ph.D. in Anatomy from Western Reserve University in 1957. Dr. Arquilla completed his residency in Pathology in 1959 and received his Board Certification in Anatomic Pathology in 1963.
RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at IR@Radient-Pharma.com or 1.206.310.5323.
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of our Onko Sure™ In Vitro Diagnostic cancer test. Our focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Radient Pharmaceutical’s current Onko-Sure™ cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.
Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
RPC Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
Tel: 206.310.5323
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
